Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

David T. Teachey, Stephan A. Grupp, Valerie Brown

Research output: Contribution to journalReview article

94 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.

Original languageEnglish (US)
Pages (from-to)569-580
Number of pages12
JournalBritish Journal of Haematology
Volume145
Issue number5
DOIs
StatePublished - Jun 1 2009

Fingerprint

Hematologic Neoplasms
Sirolimus
Leukemia
Hematologic Diseases
Therapeutics
Anaplastic Large-Cell Lymphoma
Mantle-Cell Lymphoma
Cell Cycle Proteins
Lymphoproliferative Disorders
Protein-Serine-Threonine Kinases
Immunosuppressive Agents
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphatidylinositol 3-Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Signal Transduction
Clinical Trials
Growth

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{7e5302bf17d34e5585a7ab6e02e3c9ea,
title = "Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies",
abstract = "The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.",
author = "Teachey, {David T.} and Grupp, {Stephan A.} and Valerie Brown",
year = "2009",
month = "6",
day = "1",
doi = "10.1111/j.1365-2141.2009.07657.x",
language = "English (US)",
volume = "145",
pages = "569--580",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. / Teachey, David T.; Grupp, Stephan A.; Brown, Valerie.

In: British Journal of Haematology, Vol. 145, No. 5, 01.06.2009, p. 569-580.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

AU - Teachey, David T.

AU - Grupp, Stephan A.

AU - Brown, Valerie

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.

AB - The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, protein synthesis, and cell-cycle progression through interactions with a number of signalling pathways, including PI3K/AKT, ras, TCL1, and BCR/ABL. Many haematological malignancies have aberrant activation of the mTOR and related signalling pathways. Accordingly, mTOR inhibitors, a class of signal transduction inhibitors that were originally developed as immunosuppressive agents, are being investigated in preclinical models and clinical trials for a number of haematological malignancies. Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies. Promising early clinical data suggests activity of mTOR inhibitors in a number of haematological diseases, including acute lymphoblastic leukaemia, chronic myeloid leukaemia, mantle cell lymphoma, anaplastic large cell lymphoma, and lymphoproliferative disorders. This review describes the rationale for using mTOR inhibitors in a variety of haematological diseases with a focus on their use in leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=66149164593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149164593&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07657.x

DO - 10.1111/j.1365-2141.2009.07657.x

M3 - Review article

C2 - 19344392

AN - SCOPUS:66149164593

VL - 145

SP - 569

EP - 580

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -